These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38491717)

  • 41. Metabolism and disposition of ABT-894, a novel α4β2 neuronal acetylcholine receptor agonist, in mice and monkeys.
    Liu H; Fu W; Wetter J; Xu H; Guan Z; Stuart P
    Xenobiotica; 2014 Jun; 44(6):531-40. PubMed ID: 24479584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
    Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
    Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment.
    Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
    Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disposition and metabolic fate of clentiazem in rats and dogs.
    Nakamura S; Sugawara Y; Fukushima T; Ito Y; Ohashi M; Takaiti O
    Biol Pharm Bull; 1993 Jul; 16(7):647-55. PubMed ID: 8401396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
    Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
    Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans.
    Kogame A; Lee R; Pan L; Sudo M; Nonaka M; Moriya Y; Higuchi T; Tagawa Y
    Xenobiotica; 2019 Apr; 49(4):433-445. PubMed ID: 29557709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
    Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
    Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison and identification of metabolic profiling of bicyclol in rats, dogs and humans in vitro and in vivo.
    Hu M; Li Y; You F; Bai J; Fan X; Zhao S; Sun Y; Wang B; Hu J; Li Y
    Eur J Pharm Sci; 2020 Nov; 154():105518. PubMed ID: 32818657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and metabolism of HOE 077. Preclinical studies.
    Kellner HM; Volz M; Badder E; Kürzel GU; Eckert HG
    J Hepatol; 1991; 13 Suppl 3():S48-61; discussion S62. PubMed ID: 1667669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry.
    Muehlan C; Fischer H; Zimmer D; Aissaoui H; Grimont J; Boss C; Croft M; van Gerven J; Krähenbühl S; Dingemanse J
    Curr Drug Metab; 2019; 20(4):254-265. PubMed ID: 30727881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.